<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005993</url>
  </required_header>
  <id_info>
    <org_study_id>1999LS022</org_study_id>
    <secondary_id>MT1998-21</secondary_id>
    <secondary_id>NCI-G00-1803</secondary_id>
    <nct_id>NCT00005993</nct_id>
  </id_info>
  <brief_title>Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer</brief_title>
  <official_title>Immunotherapy With Subcutaneous Il-2 and Stem Cell Factor (SCF) for Patients With Lymphoma or Breast Cancer After Autologous Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.&#xD;
      Filgrastim and stem cell factor may increase the number of immune cells found in bone marrow&#xD;
      or peripheral blood and may help a person's immune system recover from the side effects of&#xD;
      cancer therapy. Peripheral stem cell transplantation may be able to replace immune cells that&#xD;
      were destroyed by therapy used to kill cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of interleukin-2 and stem cell factor&#xD;
      following peripheral stem cell transplantation in treating patients who have non-Hodgkin's&#xD;
      lymphoma, Hodgkin's disease, or advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the safety and maximum tolerated dose of interleukin-2 (IL-2) and&#xD;
      stem cell factor (SCF) following autologous peripheral blood stem cell transplantation in&#xD;
      patients with non-Hodgkin's lymphoma or advanced breast cancer. II. Determine the&#xD;
      effectiveness of filgrastim (G-CSF) and SCF as mobilizing agents in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of stem cell factor (SCF). Patients receive&#xD;
      filgrastim (G-CSF) subcutaneously (SC) followed by SCF SC daily for 7-10 days. Beginning on&#xD;
      the fifth day of G-CSF and SCF injections, peripheral blood stem cells (PBSC) are collected&#xD;
      over several days. PBSC are later reinfused and patients receive G-CSF SC daily until&#xD;
      hematopoietic recovery. At least 30 days but no later than 110 days following transplant,&#xD;
      patients who did not experience adverse reactions to SCF during mobilization begin&#xD;
      posttransplant immunotherapy. Patients receive interleukin-2 SC daily and SCF SC 3 times&#xD;
      weekly for 6 weeks. Treatment continues in the absence of unacceptable toxicity or disease&#xD;
      progression. Cohorts of 3-6 patients receive escalating doses of SCF during posttransplant&#xD;
      immunotherapy until the maximum tolerated dose (MTD) is determined. The MTD is defined as the&#xD;
      dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.&#xD;
      Patients are followed at 1 week, every 3 months for 1 year, and then every 6 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 27 patients will be accrued for this study within 1-1.5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 1999</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human stem cell factor</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Hodgkin's disease, non-Hodgkin's lymphoma, or advanced stage&#xD;
        breast cancer Planned treatment is autologous peripheral blood stem cell transplantation No&#xD;
        T-cell lymphomas Hormone receptor status: Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 to 65 Menopausal status: Not specified Performance status:&#xD;
        Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not&#xD;
        specified Renal: Not specified Immunologic: No history of seasonal or recurrent asthma&#xD;
        within the past 5 years No concurrent asthmatic symptoms (e.g., wheezing) related to a&#xD;
        current respiratory tract infection No anaphylactic/anaphylactoid type event manifested by&#xD;
        disseminated urticaria, laryngeal edema, hypotension, and/or bronchospasm (e.g., food or&#xD;
        insect venom) within the past 5 years Drug allergies manifested solely by rash allowed No&#xD;
        history of angioedema or recurrent urticaria lasting longer than 14 days No history of&#xD;
        hereditary or acquired angioedema No known allergy to E. coli derived products Other: Not&#xD;
        pregnant Negative pregnancy test Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 1 week&#xD;
        since prior hematopoietic growth factors Chemotherapy: Not specified Endocrine therapy: No&#xD;
        concurrent steroids Radiotherapy: No concurrent radiotherapy Surgery: Not specified Other:&#xD;
        No concurrent beta adrenergic blocking agents No concurrent therapeutic antibiotics&#xD;
        posttransplant No concurrent IV hyperalimentation or IV fluids posttransplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda J. Burns, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>June 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2004</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

